168 related articles for article (PubMed ID: 27434411)
1. Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.
von Mässenhausen A; Sanders C; Brägelmann J; Konantz M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Lengerke C; Perner S
Int J Cancer; 2016 Nov; 139(10):2359-69. PubMed ID: 27434411
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma.
Xu J; Lu W; Zhang S; Zhu C; Ren T; Zhu T; Zhao H; Liu Y; Su J
Cancer Biol Ther; 2014 May; 15(5):612-22. PubMed ID: 24556606
[TBL] [Abstract][Full Text] [Related]
3. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
4. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
Hedberg ML; Goh G; Chiosea SI; Bauman JE; Freilino ML; Zeng Y; Wang L; Diergaarde BB; Gooding WE; Lui VW; Herbst RS; Lifton RP; Grandis JR
J Clin Invest; 2016 Jan; 126(1):169-80. PubMed ID: 26619122
[TBL] [Abstract][Full Text] [Related]
5. MERTK as a novel therapeutic target in head and neck cancer.
von Mässenhausen A; Sanders C; Thewes B; Deng M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Heasley L; Brägelmann J; Perner S
Oncotarget; 2016 May; 7(22):32678-94. PubMed ID: 27081701
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
9. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
Lin YC; Wu MH; Wei TT; Lin YC; Huang WC; Huang LY; Lin YT; Chen CC
Oncotarget; 2014 Jan; 5(1):298-308. PubMed ID: 24457597
[TBL] [Abstract][Full Text] [Related]
10. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
11. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
[TBL] [Abstract][Full Text] [Related]
12. Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Li HM; Yang JG; Liu ZJ; Wang WM; Yu ZL; Ren JG; Chen G; Zhang W; Jia J
J Exp Clin Cancer Res; 2017 Jan; 36(1):7. PubMed ID: 28061878
[TBL] [Abstract][Full Text] [Related]
13. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
15. IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK.
Lehman CE; Spencer A; Hall S; Shaw JJP; Wulfkuhle J; Petricoin EF; Bekiranov S; Jameson MJ; Gioeli D
Sci Rep; 2021 May; 11(1):10826. PubMed ID: 34031486
[TBL] [Abstract][Full Text] [Related]
16. Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.
Sun SS; Zhou X; Huang YY; Kong LP; Mei M; Guo WY; Zhao MH; Ren Y; Shen Q; Zhang L
Mol Cancer; 2015 Dec; 14():213. PubMed ID: 26690371
[TBL] [Abstract][Full Text] [Related]
17. Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts.
Görögh T; Quabius ES; Heidebrecht H; Nagy A; Muffels T; Haag J; Ambrosch P; Hoffmann M
Int J Cancer; 2016 May; 138(10):2529-38. PubMed ID: 26756583
[TBL] [Abstract][Full Text] [Related]
18. 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.
Kerk SA; Finkel KA; Pearson AT; Warner KA; Zhang Z; Nör F; Wagner VP; Vargas PA; Wicha MS; Hurt EM; Hollingsworth RE; Tice DA; Nör JE
Clin Cancer Res; 2017 May; 23(10):2516-2527. PubMed ID: 27780858
[No Abstract] [Full Text] [Related]
19. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M
Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
